As of today (2024-06-05), ClouDr Group's share price is HK$2.64.
ClouDr Group's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.53. Hence, ClouDr Group's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for ClouDr Group's Price-to-Free-Cash-Flow or its related term are showing as below:
HKSE:09955's Price-to-Free-Cash-Flow is not ranked *
in the Medical Distribution industry.
Industry Median: 17.44 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 18.90% per year.
During the past 5 years, ClouDr Group's highest 3-Year average Free Cash Flow per Share Growth Rate was 18.90% per year. The lowest was -61.60% per year. And the median was -21.35% per year.
ClouDr Group Price-to-Free-Cash-Flow Historical Data
The historical data trend for ClouDr Group's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ClouDr Group's Price-to-Free-Cash-Flow
For the Medical Distribution subindustry, ClouDr Group's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClouDr Group's Price-to-Free-Cash-Flow Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ClouDr Group's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where ClouDr Group's Price-to-Free-Cash-Flow falls into.
ClouDr Group Price-to-Free-Cash-Flow Calculation
ClouDr Group's Price-to-Free-Cash-Flow ratio for today is calculated as
ClouDr Group's Share Price of today is HK$2.64.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ClouDr Group's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.53.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ClouDr Group (HKSE:09955) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
ClouDr Group Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of ClouDr Group's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. Its offerings include in-hospital solutions, pharmacy solutions, and individual chronic condition management solutions. The company's in-hospital solution consists of sales of medical devices, consumables and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies. It generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:09955 has been successfully added to your